Stoke Therapeutics (STOK) Revenue (2022 - 2026)

Stoke Therapeutics' Revenue history runs 5 years deep, the most recent figure standing at $6.2 million for Q1 2026.

• On a quarterly basis, Revenue fell 96.07% year-over-year to $6.2 million in Q1 2026; TTM through Mar 2026 was $32.1 million, a 83.2% decrease from a year earlier, with the FY2025 full-year figure at $184.4 million, up 404.5% from the prior year.
• Revenue grew to $6.2 million in Q1 2026 per STOK's latest filing, from $1.4 million in the prior quarter.
• Across five years, Revenue topped out at $158.6 million in Q1 2025 and bottomed at $1.4 million in Q4 2025.
• The 5-year median for Revenue is $4.2 million (2024), against an average of $14.9 million.
• Across the five-year window, Revenue soared 3661.12% in 2025 and slumped 96.07% in 2026, its largest moves.
• Year by year, Revenue stood at $3.3 million in 2022, then retreated by 14.26% to $2.8 million in 2023, then soared by 707.07% to $22.6 million in 2024, then tumbled by 93.8% to $1.4 million in 2025, then soared by 344.29% to $6.2 million in 2026.
• Per Business Quant, the three latest STOK Revenue figures stand at $6.2 million (Q1 2026), $1.4 million (Q4 2025), and $10.6 million (Q3 2025).